GSK plc reported that its asthma drug, Nucala, significantly reduced COPD exacerbations by 21% in a trial published on April 30, 2025, with notable reductions in a chronic bronchitis subgroup and emergency hospital visits. This event holds significant importance for the company as Nucala is not yet approved for COPD treatment but is under review with the FDA.